The most effective drug to treat acute ischemic stroke, tissue plasminogen activator (tPA), must be applied within three hours after symptom onset because of the risk of hemorrhage and other complications such as neurotoxicity. The anticancer drug imatinib (Gleevec) may help overcome these limitations by counteracting the ability of tPA to increase the permeability of the blood-brain barrier ( pages 731–737 ).
No takes yet. Share an insight, caveat, or question.
A 2008 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: